Volume 3 | Issue 3 | DOI: https://doi.org/10.33696/cancerimmunol.3.051
Anti-PD1 Therapy in Lynch Syndrome-associated Recurrent Glioblastoma
- 1Senior Associate Consultant, Assistant Professor, Departments of Neurology and Neurosurgery, Mayo Clinic Florida, 4500 San Pablo Rd. S., Jacksonville, FL 32224, USA
Wendy J Sherman, Sherman.Wendy@mayo.edu
Received Date: July 07, 2021
Accepted Date: August 23, 2021
Sherman WJ. Anti-PD1 Therapy in Lynch Syndrome-associated Recurrent Glioblastoma. J Cancer Immunol. 2021; 3(3): 151-153.
Copyright: © 2021 Sherman WJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The nature of gene mutations induced by ionizing radiation in germ cells and transmitted to offspring remains one of the most important problems in radiation genetics of higher eukaryotes. The data accumulated in this field were obtained by different authors under different experimental conditions which does not give a complete insight about the nature of radiation-induced inherited mutations at different genome levels (chromosome, gene, DNA).
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
It is now well accepted that the ionizing radiation-generated reactive oxygen species (ROS), that constitute ~2/3 of the effects of external beam radiation, do not only produce direct tumor cell death, but also affect the surrounding microenvironment. Moreover, this indirect effect of radiation may result in systemic effects, specifically the initiation of an inflammatory response.
Despite the advances in diagnostic and therapeutic field, colorectal cancer (CRC) still remains the third most common cause of death worldwide, with more than 600,000 cancer-related deaths per year.
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.